TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03920449
Drug: Botulinum Toxins
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
Study: NCT01363817
Drug: BMS-906024
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01363817
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01884844
Drug: Vitamin D3, Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03081897
Drug: SPRANC Block group
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
Study: NCT03170739
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine given during surgery.
Study: NCT00820755
Drug: Cetuximab 250 mg/m^2
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
Study: NCT04179396
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral rucaparib will be administered twice daily
Study: NCT04179396
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved.
Study: NCT04179396
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone will be administered once daily with prednisone
Study: NCT00716625
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition.
Study: NCT01676285
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01690780
Drug: Oral morphine
Normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
Study: NCT00006093
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04538391
Drug: local ifiltration Bupivacaine, Meloxican and placebo
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no other intervention done
Study: NCT02082678
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
Study: NCT03301181
Drug: BGB-3111 (Arm A)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 320 mg BGB-3111 single oral dose
Study: NCT04803162
Drug: Omeprazole 20 MG Oral Tablet
Normalized name: omeprazole 20 MG Oral Tablet
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
Study: NCT01531790
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1, AUC 5, i.v.
Study: NCT03301181
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin once daily
Study: NCT03301181
Drug: BGB-3111 (Arm B)
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 80 mg BGB-3111 single oral dose
Study: NCT03301181
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg itraconazole once daily
Study: NCT01531790
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: d1, 500 mg/m2, i.v.
Study: NCT01531790
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
Study: NCT03145623
Drug: Elbasvir and Grazoprevir
Normalized name: elbasvir and grazoprevir
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
Study: NCT00003725
Drug: valrubicin
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01572662
Drug: Fludarabine monophosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 by vein on Days -6 through -3.
Study: NCT01572662
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
Study: NCT02349178
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
Study: NCT02349178
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
Study: NCT01572662
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
Study: NCT01572662
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
Study: NCT03279250
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03279250
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03279250
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00743340
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
Study: NCT01929460
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ciprofloxacin oral capsule (one capsule twice a day for 3 days)
Study: NCT00244595
Drug: candsartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04560231
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
Study: NCT02754076
Drug: AX 250
Normalized name: Tindamax 250mg Tablet
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
Study: NCT03520972
Drug: PB-119 75ug
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 eligible patients will be included in this group
Study: NCT03520972
Drug: PB-119 150ug
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 eligible patients will be included in this group
Study: NCT03520972
Drug: PB-119 200ug
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 eligible patients will be included in this group
Study: NCT00018460
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001191
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001191
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02509143
Drug: Intravenous infusion of ramosetron
Normalized name: OIL OF CAMPHOR
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea.
Study: NCT01860638
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
Study: NCT01860638
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
Study: NCT03899454
Drug: Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract
Normalized name: Garcinia mangostana fruit rind extract
DrugBank: Mango (DB10657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
Study: NCT01860638
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
Study: NCT01756885
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
Study: NCT01221571
Drug: AFM 13
Normalized name: AFM-13
DrugBank: Acimtamig (DB18674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
Study: NCT00273000
Drug: GLP-2
Normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00897676
Drug: Exendin-(9-39)
Normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-500pmol/kg/min
Study: NCT01987505
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1400 mg will be injected subcutaneously (SC).
Study: NCT01833520
Drug: Ra-223 Dichloride
Normalized name: RADIUM RA-223 DICHLORIDE
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
Study: NCT01328925
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days
Study: NCT04502589
Drug: Perampanel Tablet
Normalized name: Perampanel Tablets
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
Study: NCT00051155
Drug: Travoprost (0.004%)
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00051155
Drug: Latanoprost (0.005%)/Timolol (0.5%)
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00023764
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01009476
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
Study: NCT02407704
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02407704
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
Study: NCT00690495
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (drug), intravenous, induction of anesthesia
Study: NCT00690495
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (drug), intravenous, induction of anesthesia
Study: NCT02504450
Drug: Adasuve
Normalized name: Adasuve
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled medication to treat acute agitation in the emergency department
Study: NCT02504450
Drug: Alternative medications
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication given to treat acute agitation in the emergency department
Study: NCT01685255
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03917914
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As in arm description
Study: NCT01685255
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00577655
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
Study: NCT01632423
Drug: bimatoprost 0.01%
Normalized name: BIMATOPROST 0.01% OPH SOLN
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Study: NCT03926169
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Study: NCT03926169
Drug: Placebo for risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for risankizumab is administered as a SC injection in PFS
Study: NCT00837564
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
Study: NCT03851237
Drug: 64Cu-DOTA-ECLIi
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
Study: NCT03473132
Drug: four factor prothrombin complex concentrate
Normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
Study: NCT03598595
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03598595
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03598595
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00945490
Drug: NX-1207
Normalized name: NX-1207
DrugBank: NX-1207 (DB05493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraprostatic injection of 2.5 mg NX-1207
Study: NCT02903537
Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
Normalized name: MONOCYTE-DERIVED NEUTROPHIL CHEMOTACTIC FACTOR
DrugBank: Human Interleukin 8 (DB16456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranodal administration
Study: NCT02757703
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
Study: NCT02757703
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
Study: NCT02757703
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
Study: NCT03519646
Drug: Eliglustat
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test.
Study: NCT01937117
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV